Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
22 août 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that management will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference.
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
14 août 2024 21h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter ended June 30, 2024, and provided a business update.
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
14 août 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter ended June 30, 2024, and provided a business update.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 août 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
01 août 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that it will report second quarter 2024 financial results and provide a business update on Wednesday, August 14, 2024.
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
29 juil. 2024 07h35 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the signing of a co-promotion agreement with Kowa Pharmaceuticals America, Inc.
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
29 juil. 2024 07h30 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis.
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
23 juil. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the submission of an sNDA in scalp and body psoriasis.
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
22 juil. 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis will host a KOL virtual event July 29, 2024
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
09 juil. 2024 16h53 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis announced the FDA approval for ZORYVE (roflumilast) cream, 0.15%, for the treatment of atopic dermatitis